SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-017520
Filing Date
2024-02-27
Accepted
2024-02-27 16:05:29
Documents
16
Period of Report
2024-02-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0200797-8k_immucell.htm   iXBRL 8-K 26838
2 PRESS RELEASE OF IMMUCELL CORPORATION DATED FEBRUARY 27, 2024 ea0200797ex99-1_immucell.htm EX-99.1 58486
6 GRAPHIC ex99-1_001.jpg GRAPHIC 2680
  Complete submission text file 0001213900-24-017520.txt   271280

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE iccc-20240227.xsd EX-101.SCH 3015
4 XBRL LABEL FILE iccc-20240227_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE iccc-20240227_pre.xml EX-101.PRE 22359
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0200797-8k_immucell_htm.xml XML 3492
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

IRS No.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 24686491
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)